Latest Intellectual Property News

AdAlta Limited is accelerating its 'East to West' cellular immunotherapy strategy, aiming to bridge Asian innovation with Western clinical development and manufacturing to target solid cancers. The company plans to secure three assets by the end of 2025 and initiate clinical trials, positioning itself as a leader in this emerging market.

Terra Uranium has laid out a comprehensive 2025 exploration strategy targeting multiple projects in the Athabasca Basin, leveraging partnerships and advanced geophysics to accelerate uranium discovery efforts.

BlueBet has announced a strategic acquisition of TopSport, supported by a $15 million equity raise, aiming to boost market share and deliver significant earnings accretion by FY26.

Little Green Pharma has finalized the acquisition of Health House, a key medicinal cannabis distributor, for a fraction of its previous valuation, marking a strategic move to deepen vertical integration.

Neurizon Therapeutics has been granted a pivotal US patent for its lead drug candidate NUZ-001, extending protection until 2039 and enhancing its commercial and clinical positioning in neurodegenerative disease treatment.

Sunrise Energy Metals has updated its Syerston Scandium Project Mineral Resource Estimate, confirming a substantial global resource and planning a targeted drilling campaign to expand high-grade zones. The company is advancing product development with key partners amid growing demand for scandium in strategic sectors.

Biome Australia has partnered with the Food and Beverage Accelerator (FaBA) to jointly develop its promising BMB18 probiotic strain, leveraging $50 million in Australian government funding while retaining full IP ownership.

PARKD Ltd has secured a 7-day extension to its exclusive licence agreement with Fielders Steel Roofing, following successful proof-of-concept projects for its Metal Deck Support System. The extension aims to finalise terms for a longer-term commercial partnership.

Argo Investments reports a robust half-year profit of $121.2 million and announces a record fully franked interim dividend of 17.0 cents per share, driven by increased dividend revenue and strategic portfolio moves.

Recce Pharmaceuticals has gained key regulatory and ethics approvals for its Phase 3 clinical trial in Indonesia and completed patient dosing for its Phase II trial, while securing a substantial A$6.75 million R&D tax rebate to bolster its financial position.

Hexima Limited has called off its planned acquisition of AI developer Real Thing Entertainment, ending the quarter with $1.64 million in cash and a cautious outlook on future strategic moves.

Purifloh Limited has made significant progress in its PFAS destruction technology, securing a $100,000 BRII feasibility grant while navigating challenges to resume trading on the ASX.